Health AI Central
Peer-Reviewed Publication
Lung Cancer2026;220109586.August 20, 2026Journal Article

Therapeutic evolution: Adoption of newly approved systemic therapies in resected stage IB-IIIA NSCLC in the United States.

Jhanelle E Gray1, Kelli Thoele2, Madeline Richey3, Nada Boualam4, Karen Schwed5, Erich Brechtelsbauer6, Qinli Ma7, Kristin M Sheffield8
1H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, United States. Electronic address: jhanelle.gray@moffitt.org.
2Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, United States. Electronic address: thoele_kelli@lilly.com.
3Flatiron Health, 233 Spring Street, New York, NY 10013, United States. Electronic address: madeline.richey@flatiron.com.
4Flatiron Health, 233 Spring Street, New York, NY 10013, United States. Electronic address: nada.boualam@flatiron.com.
5Flatiron Health, 233 Spring Street, New York, NY 10013, United States. Electronic address: karen.schwed@flatiron.com.
6Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, United States. Electronic address: erich.brechtelsbauer@lilly.com.
7Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, United States. Electronic address: ma_qinli@lilly.com.
8Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, United States. Electronic address: sheffield_kristin_m@lilly.com.
PubMed DOI

Abstract

OBJECTIVES: Evidence is limited regarding use of immunotherapies and targeted therapies in early-stage and locally advanced non-small cell lung cancer (NSCLC) in clinical practice. This retrospective, observational cohort study used health records from US oncology practices to describe treatment patterns and evaluate outcomes in patients with resected stage IB-IIIA NSCLC. MATERIALS AND METHODS: A…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.